I was not expecting Biodel to advance an RHI formulation anyway. It has been just about the analogs for some time. Those formulations work better for obvious reasons. Just have to team up with either Sanofi, Ely or Novo since they own the respective patents. But they are motivated b/c the clock is ticking on those patents. We've solved the tolerability issue, it works faster and when using an analog its a faster "out" also. So this is where Biodel's future is. Now is probably the bottom in the stock and I might finally increase my position.